Manpreet Kaur, MD | |
71 Haynes St, Manchester, CT 06040-4131 | |
(860) 647-6827 | |
(860) 533-3452 |
Full Name | Manpreet Kaur |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 71 Haynes St, Manchester, Connecticut |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144633546 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 54032 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Manpreet Kaur, MD 71 Haynes St, Manchester, CT 06040-4131 Ph: (860) 647-6827 | Manpreet Kaur, MD 71 Haynes St, Manchester, CT 06040-4131 Ph: (860) 647-6827 |
News Archive
Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.
QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.
A retrospective analysis of large datasets of biomarkers from tumors and healthy tissue by researchers at the Johns Hopkins Kimmel Cancer Center Convergence Institute suggests that older cancer patients could benefit as much as younger patients from cancer immunotherapies.
Cancer molecular testing can drive clinical decision making and help a clinician determine if a patient is a good candidate for a targeted therapeutic drug.
According to Associated Press sources, "The nation's drugmakers stand ready to spend $150 million to help President Barack Obama overhaul health care this fall, according to numerous officials, a staggering sum that could dwarf attempts to derail his chief domestic priority ...
› Verified 3 days ago
Dr. Allana R Lee, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-646-1222 | |
Michael John Dewberry, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 | |
Dr. Constantine Zariphes, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 150 N Main St, Manchester, CT 06042 Phone: 860-533-3434 Fax: 860-647-6829 | |
Dr. Anees Ahmed, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 357 E Center St, #2, Manchester, CT 06040 Phone: 860-649-1178 | |
Jonathan L Chasen, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 444 Center St, Manchester, CT 06040 Phone: 860-646-3888 Fax: 860-645-4132 | |
Dr. Joseph E. Podolski, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Department Of Psychiatry, Manchester, CT 06040 Phone: 860-647-6831 |